GlassScriptPhysician profile
Huilin Li
NPI 1003925041
$1,698.80
in general payments reported to CMS, 2019-2025
17 companies · $23.72 in 2025
The $23.72 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2022: $148 · 2023: $612 · 2024: $724 · 2025: $23.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.61 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $485.39 | 2023-2024 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $195.62 | 2022-2024 | Xarelto |
| Cumberland Pharmaceuticals, INC. | $175.07 | 2022-2024 | Caldolor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.10 | 2024-2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $122.07 | 2024 | Ingrezza |
| Pfizer INC. | $108.69 | 2022-2024 | |
| Vifor Pharma, INC. | $97.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.34 | 2019 | |
| Merck Sharp & Dohme LLC | $65.81 | 2022-2024 | Dificid, Zerbaxa |
| Novartis Pharmaceuticals Corporation | $45.22 | 2024 | |
| Astellas Pharma US INC | $44.99 | 2023 | |
| Amgen INC. | $27.84 | 2022 | |
| Heartflow, INC. | $25.37 | 2024 | |
| Abbvie INC. | $21.74 | 2024 | |
| Mallinckrodt Hospital Products INC. | $20.29 | 2023 | Terlivaz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.91 | 2022 | |
| Neurelis, INC. | $18.27 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huilin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.